Back to Search
Start Over
Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy.
- Source :
-
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2022 May; Vol. 40 (5), pp. 988-992. Date of Electronic Publication: 2021 Jul 07. - Publication Year :
- 2022
-
Abstract
- Objectives: Adiponectin is an adipokine that plays a relevant role in the development of metabolic syndrome (MetS), a complication that increases the risk of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA). Accordingly, we assessed for the first time the short-term effect of anti-IL-6 receptor tocilizumab (TCZ) administration on adiponectin serum levels in RA patients and explored the potential association of adiponectin levels with MetS features, other CV risk factors and demographic and clinical characteristics of these patients.<br />Methods: Adiponectin serum levels were evaluated in 50 non-diabetic RA patients, undergoing TCZ treatment, immediately prior to (pre-infusion) and 60 minutes after the end of a TCZ intravenous infusion (post-infusion).<br />Results: No significant differences in adiponectin levels pre- and post-TCZ infusion were found in RA patients (p=0.69). Patients with obesity exhibited decreased basal levels of adiponectin with respect to those non-obese (p=0.03). Additionally, a negative association of adiponectin basal levels with body mass index, insulin, insulin/glucose index, C-peptide and leptin levels (p<0.01; p=0.02; p=0.03; p=0.03 and p=0.01, respectively), as well as a positive correlation with HDL-cholesterol levels (p<0.001) was seen.<br />Conclusions: Our results support the claim that low adiponectin may contribute to the development of MetS and, consequently, CV disease in RA. Anti-IL-6 therapy does not seem to exert a short-term effect on adiponectin levels.
Details
- Language :
- English
- ISSN :
- 0392-856X
- Volume :
- 40
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical and experimental rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 34251326
- Full Text :
- https://doi.org/10.55563/clinexprheumatol/p8nx80